# OnCo record tabelecleucel (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/tabelecleucel/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "tabelecleucel" ;
  schema:name "Tabelecleucel"@en ;
  schema:alternateName "Ebvallo"@en, "ATA129"@en, "tab-cel"@en ;
  schema:description "Tabelecleucel is a bank of donor T cells trained against Epstein-Barr virus, approved in Europe in 2022 as the first off-the-shelf T-cell therapy, for EBV-driven lymphoma after transplant when rituximab has failed."@en ;
  schema:url <https://onco.cc/drugs/tabelecleucel/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Tabelecleucel> ;
  schema:citation <https://clinicaltrials.gov/search?intr=Tabelecleucel> ;
  onco:status "approved" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "Cell therapy: allogeneic off-the-shelf Epstein-Barr virus-specific T cells" ;
  onco:approval "EU 2022: Relapsed or refractory EBV-positive post-transplant lymphoproliferative disease after at least one prior therapy" ;
  onco:cancers <https://onco.cc/cancers/post-transplant-lymphoproliferative-disorder/> ;
  onco:technologies <https://onco.cc/technologies/virus-specific-t-cells/> ;
  onco:companies <https://onco.cc/companies/atara-biotherapeutics/>, <https://onco.cc/companies/pierre-fabre/> ;
  onco:trials <https://onco.cc/trials/nct03394365/>, <https://onco.cc/trials/nct04554914/> .